Abstract:Objective To determine whether administration of exogenous human chorionic gonadotrophin (hCG) treatment improve the pregnancy outcome in first trimester threatened miscarriages. Design A prospective, double blind, randomised, placebo-controlled trial.Setting The Early Pregnancy Assessment Unit, Royal Bolton Hospital, Bolton, United Kingdom.Population One hundred and eighty-three women with vaginal bleeding and a viable fetus seen on ultrasound scan (USS) in the first 12 weeks of pregnancy. Methods The patient… Show more
“…With the accumulating evidence of the involvement of hCG forms in pregnancy failures and potential miscarriages (1-3, 14, 17, 37, 38), Qureshi et al (38) investigated the use of intramuscular injections of hCG to prevent failures. No difference was observed between women who received hCG and those who received placebo.…”
Section: Sasaki Hcg-h and Pregnancy Failure Fertil Steril 2008mentioning
“…With the accumulating evidence of the involvement of hCG forms in pregnancy failures and potential miscarriages (1-3, 14, 17, 37, 38), Qureshi et al (38) investigated the use of intramuscular injections of hCG to prevent failures. No difference was observed between women who received hCG and those who received placebo.…”
Section: Sasaki Hcg-h and Pregnancy Failure Fertil Steril 2008mentioning
“…These include bed rest, 5 abstention from coitus and a simple wait and watch policy, as well as treatment with progesterone or human gonadotropin. 6,7 Progesterone deficiency is recognized to be associated with insufficient endometrial maturation and inadequate regulations, such as interleukins. Support with progestogen may therefore help to establish an adequate immune response in early pregnancy and prevent pregnancy loss.…”
“…Whereas, other study still questionned the efficacy of progesterone supplementation due to small sample size of published randomized trials [19]. However, supplementation with -hCG had no potential advantange to overcome threatened miscarriage [20].…”
Introduction. Most of miscarriage events occurred during the first trimester of pregnancy. Recent studies found the beneficial effects of maternal serum markers to predict pregnancy outcomes. However, study in Indonesian setting was still limited, especially in outpatient setting. The aim of this study was to evaluate serum progesterone and -hCG measurement as a beneficial predictor of miscarriage. Materials and Methods. This was a prospective study recruiting outpatients pregnant women in Aceh who seek first medical attention for their pregnancy during January 2013 to January 2015. Serum progesterone and -hCG level were measured beside routine obstetric procedure. The discrimination attained between miscarriage and non-miscarriage groups of pregnant women at the end of first trimester was evaluated using logistic regression and receiver operating curve analysis. Results. Among 70 pregnant recruited in this study, nineteen of them (27.1%) experienced miscarriage. Serum progesterone level of women in miscarriage group was lower than non-miscarriage group ) ng/dl vs 33.67 , p < 0.001). Serum -hCG level was also lower in miscarriage group (10 681 (IQR 5 787.5-26 577.5) mIU/ml vs 48 109 (IQR 17 137-93 915) mIU/ml, p = 0.001). Single progesterone measurement gave a good predictor ability for miscarriage with 82.2% accuracy, 86.3% sensitivity and 73.7% specificity if 19.5 ng/dl was used as a cut-off point. Conclusion. Maternal serum progesterone level could be a good predictor for miscarriage during the first trimester of pregnancy. Single -hCG serum in combination with progesterone serum measurement only had little added value for predicting miscarriage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.